Why previous treatment is the first thing to clarify
Immunotherapy helps the immune system act against cancer, but whether it is appropriate depends on the cancer and an individual assessment. That single sentence from the National Cancer Institute explains why your treatment history matters more than the general reputation of immunotherapy. A checkpoint inhibitor, a cell-based therapy and a therapeutic vaccine are different approaches, and a hospital cannot judge suitability from a diagnosis name alone.
Previous treatment is not background detail. It shapes which options remain reasonable, what safety concerns the treating team must weigh, and whether a new agent could interact with ongoing therapy. If you have already received an immunotherapy drug, the team needs to know which one, for how long, and what happened. If you have not, the team needs to know what you have received instead, because prior chemotherapy, targeted therapy, radiotherapy or surgery can all affect how a new treatment is considered.
This is why a message that says only 'I have cancer and want immunotherapy in China' rarely produces a useful reply. A message that names the tumour type, the stage, the biomarkers already tested and the treatments already given gives a clinician something to assess. The goal of the first exchange is not to secure a promise of treatment. It is to find out whether your case is one the hospital can properly evaluate, and what information is still missing.
What a previous-treatment summary should contain
A previous-treatment summary is a short factual document, not a full medical archive. It should let a clinician see the sequence of what was done and what resulted. Write it in plain English, keep it to one or two pages, and attach the supporting reports separately.
For each prior treatment, record the drug or treatment name, the dates it started and stopped, the reason it stopped, and the main response or side effect. If a treatment was stopped early because of toxicity, say so. If it was stopped because the cancer progressed, say so. Those two reasons lead to different clinical questions, and a clinician reading a vague summary cannot tell them apart.
Include the biomarker results you already have, with the report dates and the laboratory that issued them. Biomarker status is often central to whether an immunotherapy approach is worth discussing, but the relevance of any specific marker belongs to the treating team. Do not send a summary that claims a marker makes you eligible. Send the report and let the clinician interpret it.
Also list your current medicines, allergies, and any significant conditions such as autoimmune disease, organ impairment or prior transplant. These are the details that change how a treating team thinks about immune-related risk. If you are unsure whether something is relevant, include it and let the clinician decide. A short note saying 'I am not sure if this matters' is more useful than an omission.
The questions that actually move the decision forward
Once your summary is in front of a clinician, the useful questions are specific. Ask whether the immunotherapy approach you have read about is appropriate for your diagnosis and stage, and on what evidence that judgement would rest. Ask whether it is available at that hospital for your situation, and if not, what alternative the team would consider. Availability is a hospital and product question, not a general fact about China, so it must be confirmed for your case rather than assumed.
Ask how your previous treatment changes the assessment. A clinician may say that prior therapy makes a particular option less suitable, or that it makes no difference to the decision. Either answer is useful because it tells you what the team is weighing. Ask what tests or records are still needed before a view can be given, and whether those tests can be done locally before you travel.
Ask how monitoring would work. Immunotherapy can cause immune-related effects that need prompt assessment, and the practical question for an overseas patient is who would monitor you and where. If you plan to return home, ask what monitoring arrangement the treating team would recommend, what information your local clinician would need, and how communication between the two would be handled. The treating team decides the clinical content of that plan; your job is to make sure the handover is discussed before you commit to travel.
Finally, ask what the team cannot tell you yet. A records-based opinion has limits, and a responsible clinician will say when a question can only be answered after examination or further testing. That is not a refusal. It is the boundary of what a remote review can establish.
What not to assume about immunotherapy in China
Several assumptions cause unnecessary confusion. The first is that all immunotherapy is the same. Checkpoint inhibitors, CAR-T cell therapy and other cell-based approaches are distinct treatments with different requirements, risks and settings. A hospital that offers one may not offer another, and a question about 'immunotherapy' in general may get a general answer that does not help you.
The second is that a drug approved or used elsewhere is automatically accessible in China for your diagnosis. Access depends on the product, the hospital, the regulatory situation and your clinical details. Do not treat a foreign approval or a published trial result as proof that the same option is available to you in China. Ask the hospital directly, and treat the answer as specific to that hospital and that moment.
The third is that you should stop or delay current treatment while you enquire. You should not. An overseas enquiry is a planning step that runs alongside your existing care. If your symptoms worsen or you need urgent assessment, local care comes first. Do not interrupt prescribed treatment to wait for a reply from another country.
The fourth is that an initial reply is a treatment decision. It is not. A hospital's first response usually establishes whether your case can be reviewed and what is missing. Suitability, hospital acceptance and any treatment plan are decided later by the treating clinicians, after they have the records and, where needed, an examination.
How to send records without oversharing
Start with a short summary by the enquiry form, email or WhatsApp. The initial contact does not require a complete medical archive, passport numbers or payment details. Describe the diagnosis, the main question and the treatments already given, then ask what the team needs next.
When you are asked for records, send them in a form a clinician can read quickly. Pathology and biomarker reports, the most recent imaging reports, the treatment summary and a current medication list cover most of what a first review needs. If a report is in another language, ask whether a translation is required and who should provide it. Do not assume a translation format; confirm it with the hospital or the coordinator handling your case.
Keep a simple index so nothing is lost. Number the documents, name each file clearly, and note the date of each report. If a record is missing, say so rather than leaving a gap that looks like an omission. A clinician who knows a scan is unavailable can ask for it; a clinician who assumes the file is complete may reach a wrong impression.
If you use a coordination service, its role is practical: helping you assemble and transmit records, arranging appointments and interpretation, and keeping track of what has been sent. Clinical interpretation, suitability and treatment decisions stay with the hospital and its licensed clinicians. Coordination fees and hospital charges are separate, and you should ask what a written estimate covers before you commit to anything.
Planning the enquiry around your own care
Treat the enquiry as a defined task with a clear question, not an open-ended search for options. Decide in advance what you want to learn: whether a specific immunotherapy approach is appropriate for your diagnosis, whether it is available at the hospital you are asking, and how monitoring would continue if you travelled. Write those three questions down and keep your correspondence focused on them.
Give the hospital enough time to review and be prepared for a request for more information. If the reply is that your case needs an examination or a test that cannot be done remotely, ask what that means for your planning. It may mean a visit is needed before any view can be given, or it may mean the team can proceed on records alone. The hospital decides which applies to you.
Keep your local oncology team informed. They hold the treatment history and can provide records, clarify dates and advise on whether travel is realistic at this point in your care. Their view on your current fitness and any restrictions belongs in the conversation, and the receiving clinician will want to know it.
A practical next step is to prepare the one-page previous-treatment summary described above and send it with your main question. An initial enquiry is free and does not commit you to buying a proxy consultation or any other service. The team can then tell you what is missing and whether a records-based review is the right next stage for your case.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.